Skip to main content
Equibles
ABCL logo

ABCL · AbCellera Biologics Inc. · Documents

Track ABCL — free

Use ABCL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ABCL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$11.62 -0.33 (-2.76%) At close · Nov 12 Play latest call Q3 2026 earnings call transcript
Rebalance outlook locked
Market Cap
$3.80B
Shares
326.62M
Volume · Nov 12 3.16M Avg daily vol (3M) 5.09M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $75.13M up 160.6% 10-K filed Feb 24, 2026 Quarterly report New FY2026 Q3 Revenue $10.64M up 18.8% 10-Q filed Nov 9, 2026 Latest results New Financial results 8-K filed Nov 9, 2026 Earnings call New Q3 2026 earnings call Held Nov 9, 2026
2026
Nov 11
Investor event
50% hot-flash reduction supports ABCL 635 late-stage development

ABCL said its ABCL 635 produced a 50% placebo-controlled hot-flash reduction in a 92-patient trial, with a clean safety profile and evidence supporting once monthly dosing, and is preparing for late stage development.

4 source passages
So we've made a transition recently, and I think we're going to talk today about ABCL 635. We showed in that data, which was a study of about 92 patients, one-to-one placebo-controlled, that we had a 50% placebo-controlled reduction in hot flashes. And we got all of that with a clean safety profile and a PK-PD relationship that looks like it supports the TPP of once monthly. And certainly we'll be moving into late stage studies for menopausal VMS next year. Open the document at this passage
Nov 9
Earnings call
ABCL635 phase-two results support planned 2027 development

ABCL635 showed a 50% placebo-adjusted reduction in moderate-to-severe hot-flash frequency in Phase 2. Abcelera plans late-stage development in 2027, raised $200 million, and ended the quarter with over $790 million in cash and marketable securities.

5 source passages
Q3 was a transformative quarter for Abcelera, driven primarily by our positive top-line phase two results for ABCL635 Expressed as a percent change from baseline, the ABCL635 group experienced an 83% reduction from baseline in daily events compared to a 33% reduction in the placebo group for a placebo-adjusted treatment difference of 50%. We expect to initiate late-stage development for menopause, VMS, in 2027. Following the release of our Phase 2 data for ABCL 635, we completed a significantly oversubscribed $200 million capital raise. Altogether we finished the quarter with over $790 million of cash and marketable securities. Open the document at this passage
Nov 9
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Quarterly report for FY2026 Q3 AI summary on its way
Revenue $10.64M ▲ 18.8% Net loss $40.76M Diluted EPS -$0.13
Aug 7
Current report 8-K
Other events AI summary on its way
Aug 5
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $4.05M ▼ 76.3% Net loss $55.43M Diluted EPS -$0.18
Jul 29
Current report 8-K
Other events AI summary on its way
Jun 17
Current report 8-K
Other events AI summary on its way
May 11
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $8.32M ▲ 96.3% Net loss $43.17M Diluted EPS -$0.14
Feb 24
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $75.13M ▲ 160.6% Net loss $146.41M Diluted EPS -$0.49
2025
Showing 1–50 of 140 documents
Key facts CIK 1703057 CUSIP 00288U106 13F (30d) 91 filings 83 filers Visit website Investor relations